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ABSTRACT
Background. Glomerular ﬁltration rate (GFR) is accepted as
the best indicator of kidney function and is commonly esti-
mated from serum creatinine (SCr)–based equations. Separate
equations have been developed for children (Schwartz equa-
tion), younger and middle-age adults [Chronic Kidney Disease
Epidemiology Collaboration (CKD-EPI) equation] and older
adults [Berlin Initiative Study 1 (BIS1) equation], and these
equations lack continuity with ageing. We developed and vali-
dated an equation for estimating the glomerular ﬁltration rate
that can be used across the full age spectrum (FAS).
Methods. The new FAS equation is based on normalized serum
creatinine (SCr/Q), where Q is the median SCr from healthy
populations to account for age and sex. Coefﬁcients for the
equation are mathematically obtained by requiring continuity
during the paediatric–adult and adult–elderly transition. Re-
search studies containing a total of 6870 healthy and kidney-
diseased white individuals, including 735 children, <18 years
of age, 4371 adults, between 18 and 70 years of age, and 1764
older adults, ≥70 years of age with measured GFR (inulin, io-
hexol and iothalamate clearance) and isotope dilution mass
spectrometry–equivalent SCr, were used for the validation.
Bias, precision and accuracy (P30) were evaluated.
Results. The FAS equation was less biased [−1.7 (95% CI −3.4,
−0.2) versus 6.0 (4.5, 7.5)] and more accurate [87.5% (85.1,
89.9) versus 83.8% (81.1, 86.5)] than the Schwartz equation
for children and adolescents; less biased [5.0 (4.5, 5.5) versus
6.3 (5.9, 6.8)] and as accurate [81.6% (80.4, 82.7) versus
81.9% (80.7, 83.0)] as the CKD-EPI equation for young and
middle-age adults; and less biased [−1.1 (−1.6, −0.6) versus
5.6 (5.1, 6.2)] and more accurate [86.1% (84.4, 87.7) versus
81.8% (79.7, 84.0)] than CKD-EPI for older adults.
Conclusions. The FAS equation has improved validity and con-
tinuity across the full age-spectrum and overcomes the problem
of implausible eGFR changes in patients which would otherwise
occur when switching between more age-speciﬁc equations.
Keywords: development and validation, FAS eGFR equation,
healthy and kidney-diseased subjects
INTRODUCTION
Glomerular ﬁltration rate (GFR) is generally accepted as the
best indicator of kidney function. As direct measurement of
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GFR is complex, GFR is commonly estimated based on serum
creatinine (SCr) concentration. Height-dependent [1, 2] and
height-independent equations [3, 4] have been suggested for
children and adolescents [5]. The Modiﬁcation of Diet in Renal
Disease (MDRD) equation [6], and the more recent Chronic
KidneyDisease Epidemiology Collaboration (CKD-EPI) equation
[7], arewidely recognized equations to estimateGFR in adults, and
the Berlin Initiative Study 1 (BIS1) equation [8] was designed for
older adults. There is also a consensus that SCr should be obtained
by isotope dilution mass spectrometry (IDMS) traceable creatin-
ine methods in all these modern equations [9].
During the last few years, we have gained experience in
developing estimated GFR (eGFR) equations for children,
adolescents and young adults [2, 4, 5]. We also studied the
way SCr concentration changes with age from birth through
100 years of age [10]. As all SCr-based eGFR equations can
be seen as gender/race/age-adjusted SCr, we have proposed a
different way to build an eGFR equation. We adjust SCr by nor-
malizing it with the median SCr value (Q) obtained in a speciﬁc
(healthy) subpopulation. Using this approach, it is possible
not only to derive eGFR equations for children, adolescents
and young adults [4, 5], but also to reshape adult equations,
like the MDRD and CKD-EPI equations, into normalized
SCr-based eGFR equations [11–13]. Many more equations
have been proposed, both for children and adults [6–8, 14–16].
A major issue is the large discrepancy in eGFR when switching
from equations developed for children to equations developed
for adults or from equations developed for adults to equations
developed for older adults.
In this article, we derive a single (age-knotted) eGFR equa-
tion that is applicable for all ages by ﬁrst normalizing SCr for
age (for children and adolescents) and gender (for adolescents
and adults). A full age spectrum (FAS) equation remediates
the discontinuity when switching from paediatric equations
to adult equations or from adult to older adults equations. As
examples of this discontinuity problem, with a clear clinical
impact, consider the following cases:
Example 1: A healthy 18-year-old male with a body height
(L) of 180 cm and SCr of 0.90 mg/dL:
Paediatric equation (Schwartz): eGFR = 0.413 × L/SCr =
0.413 × 180/0.90 = 83 mL/min/1.73 m².
Adult equation (CKD-EPI): eGFR = 141 × (0.90/0.90)−1.209
0.99318 = 124 mL/min/1.73 m².
Switching from the Schwartz equation to the CKD-EPI equation
at the age of 18 years would result in a 50% increase in eGFR.
Example 2: A female, aged 70 years, with SCr = 3.5 mg/dL:
Adult equation (CKD-EPI): eGFR = 144 × (3.5/0.7)−1.209
0.99370 = 13 mL/min/1.73 m².
Older adults equation (BIS1): eGFR = 3736 × (3.5)−0.87 ×
70−0.95 × (0.82 if female) = 18 mL/min/1.73 m².
Switching from the CKD-EPI equation to the BIS1 equation at
the age of 70 years would result in a 44% increase and move this
female subject from GFR Category 5 back to 4.
These discontinuities are physiologically implausible and
may cause confusion. Therefore, we aimed to construct an
equation for estimating eGFR that overcomes this discontinuity
and consequently ﬁts for all ages. A subsequent aim of this
study was to validate the new equation against measured GFR
(mGFR) and to compare it with the current recommended
equations for children (Schwartz equation), adults (CKD-EPI
equation) and older adults (CKD-EPI and BIS1 equations).
Recently published SCr-based eGFR equations have been
obtained by statistical modelling of mGFR data against demo-
graphic information [age, gender, ethnicity, height (for chil-
dren)] and blood marker information (e.g. SCr or cystatin C).
In this article, we develop a new eGFR equation using
population-normalized SCr. We do not base this new equation
on statistical modelling, but we connect a previously published
and validated paediatric equation [4, 5] with the previously
published and validated BIS1 equation for older adults [8],
requiring continuity across the full age-spectrum.
MATERIALS AND METHODS
Overview of study design
The current study consists of two parts, the development
and construction of the equation (see Supplementary data,
Appendix) and validation of the new equation. For the valid-
ation study, 14 different datasets were obtained to form a rep-
resentative lifespan sample of the general population and renal
disease patients from nephrology clinics, covering 735 children
and adolescents (aged <18 years), 4371 adults (aged between
18–70 years) and 1764 older adults (aged ≥70 years). These
datasets were obtained from cross-sectional cohorts in Europe
(France, Norway, Germany, UK) and the USA (Rochester, MN)
using a wide variety of GFR measurement methods and
IDMS-equivalent SCr methods. The datasets were centralized
for data analysis. According to Belgian and French laws, retro-
spective studies using anonymized data do not require Institu-
tional Review Board (IRB) approval, however, most of the
validation datasets were obtained from previous IRB-approved
studies (Berlin, Tromsø, Rochester, Saint-Etienne, Kent).
Data sources and participants
Patient characteristics of each separate database (DB) are
described in the Supplementary data, Table S1.
Data from Lyon, France. Published (DB3–6, DB11) and un-
published data (DB1–2, DB13) from Lyon, France, were collected
by the specialized Renal Function ExplorationUnit (RFEU) of the
University Hospital in Lyon. These data were collected as routine
measurements of the RFEU. Patientswere informed that their data
could be used (in an anonymous way) for research purposes.
DB1 (n = 153) contains unpublished data selected from a co-
hort of consecutive paediatric patients, aged between 3–14
years, with a suspected kidney pathology who were referred to
the paediatric nephrology department in the period January
2010–January 2012. The selection criteria for this dataset
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DB2 (n = 185) contains unpublished data, based on the same
selection criteria as DB1, but for the inulin GFR measurement
method.
DB3–5 are subsets from one larger dataset (n = 750) with
unique entries (serial measurements were omitted from the
dataset described by Selistre [17], collected between 2003
and 2010) of 10–14-year-old children (n = 273), 15–18-year-old
adolescents (n = 151) and 19–25-year-old young adults (n =
326). The database was here subdivided into subsets to allow
for better detailed comparison with the Schwartz equation
(valid for children and adolescents) and with the CKD-EPI
equation (for young adults).
DB11 represents an extended dataset from the n = 224 to
n = 310 older adult patients (>70 years) with suspected or es-
tablished renal dysfunction referred to the RFEU between
2010 and 2014 [18]. Selection criteria were age ≥70 years,
inulin measurement, enzymatic SCr and suspected or estab-
lished renal dysfunction.
DB13 (n = 1416) contains adult patients with various kidney
pathologies representing a cross section of all CKD stages. Selec-
tion criteria for this dataset were consecutive recruitment with
enzymatic SCr (after 2010) and mGFR <90 mL/min/1.73 m².
In all datasets, only subjects fromCaucasian or North African
origin were selected.
Data from Saint-Etienne (DB7). All patients (n = 203) were
>18 years old and had conﬁrmed HIV status. Patients were
Caucasian (n = 188) or of North African origin (n = 15) and
enrolled in 2011–2012 [19].
Data from Tromsø (DB8). The subjects (n = 1627) from the
Renal Iohexol Clearance Survey In Tromsø 6 (RENIS-T6), re-
cruited in 2007–08, form a representative sample of the
middle-aged general Norwegian population [20]. A total of
1521 patients were free from cardiovascular disease, diabetes,
CKD or albuminuria. A total of 33 participants had diabetes,
34 had CKD according to an mGFR<60 mL/min/1.732 and
44 had albuminuria. All subjects were Caucasian.
Data from Rochester, MN, USA (DB9, DB10). The subjects
were recruited between 2006 and 2011 from two white
community-based cohorts [21]. The Genetic Epidemiology
Network of Arteriopathy (GENOA) cohort and the Epidemi-
ology of Coronary Artery Calciﬁcation (ECAC) cohort consisted
of 687 and 406 individuals with complete data, respectively.
ECAC was representative of the general population and
GENOA of the hypertensive population.
Data from Berlin, Germany (DB12). The BIS recruited 570
subjects, aged ≥70 years, in 2010 and 2011 with eight iohexol
measurement samples [8]. This cross-sectional dataset was
obtained from the random community-based population of
the largest statutory health insurance in Berlin. All participants
were Caucasian.
Data from Kent, UK (DB14). Participants (n = 394) from
this prospective cohort were recruited between 2008 and 2011
from nephrology clinics (38%) and the community (62%) [22].
All participants were Caucasian and >74 years of age. About
55% were hypertensive, 19% had diabetes and 44% had a
vascular disease.
Measurements
GFR measurements. Participants were asked fast for at least
4–6 h before the GFR measurement, except for water intake.
Iohexol measurement. In Lyon (DB1, DB13) and Saint-
Etienne, France (DB7) and Kent, UK (DB14), the slope-
intercept iohexol method with Bröchner-Mortensen correction
was used [23]. Lyon and Kent used three samples (120, 180
and 240 min) and Saint-Etienne used two samples (120 and
240 min) after intravenous bolus injection of iohexol (Omnipa-
que 240 or 300, GE Healthcare).
In Tromsø, Norway (DB8), GFR was measured as the single-
sample plasma clearance of iohexol (Jacobsson's method [24]).
Details have been published previously [25].
In Berlin, blood samples were obtained at 30, 60, 90, 120,
150, 180, 240 and 300 min after injection of 5 mL iohexol.
The concentration–time curve was ﬁtted and the area under
the curve was calculated using a two-compartment model.
In all cohorts, iohexol concentration in the plasma samples
was assayed by high-performance liquid chromatography.
Inulin measurement (DB2–6, DB11). GFR was measured
by renal clearance of inulin (polyfructosan infusion, Inutest,
Fresenius Kagi, Graz, Austria) [26] using a continuous infusion
of inulin after a loading dose and urine collection. Inulin clear-
ance was calculated using the standard UV/P formula [(urinary
inulin × urine ﬂow)/plasma inulin]. Plasma and urine polyfruc-
tosan measurements were obtained with the same enzymatic
method [27].
Iothalamate measurement (DB9, DB10). GFR was mea-
sured from the clearance of non-radiolabelled iothalamate
assayed with capillary electrophoresis from timed plasma (P)
and urine (U) samples [21].
Serum creatinine measurement. SCr was measured by
enzymatic IDMS-traceable methods in Lyon (after 2010), Saint-
Etienne, Tromsø, Berlin and Rochester, or directly by IDMS in
Kent. Before 2010, the SCr assay results in Lyon were calculated
back to the IDMS-equivalent SCr concentration [8, 17–22].
Data analysis
Development of the FAS equation. The current study pre-
sents a new SCr-based eGFR equation, called the FAS equation:
FAS eGFR ¼ 107:3ðSCr=QÞ for 2  age  40 years
FAS eGFR ¼ 107:3ðSCr=QÞ  0:988
ðAge40Þ for age .40 years
Q-values are themean ormedian SCr value for age-/sex-speciﬁc
healthy populations, listed in Table 1, obtained from a previous
SCr reference interval study [10]. Q was matched with age or
with median height obtained from Belgian national growth
curves [5]. The development and derivation of the FAS equa-
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GFR estimating equations. The following equations were
evaluated for children and adolescents:
• Schwartz equation: eGFR = 0.413 × L/SCr [1]
• FAS equation, with Q matching age (Table 1) [5]
• FAS-height equation, with Q matching height (Table 1) [5]
and for adults:
• CKD-EPI equation [7]
• FAS equation withQ = 0.70 mg/dL for females andQ = 0.90
mg/dL for males
and for the oldest adults we also added the comparison results
of the BIS1 equation [8].
Statistical analysis
Performance results of eGFR equations are presented as bias
(constant bias: eGFR–mGFR; proportional bias: eGFR/mGFR),
precision [root mean square error (RMSE)] and accuracy (P10
and P30, deﬁned as the percentage of patients within 10% and
30% of mGFR, respectively), along with 95% CIs. Paired t-tests
to compare bias and McNemar's test to compare proportions
were used. Statistical signiﬁcance was considered at the 5%
signiﬁcance level. A Bland–Altman plot (difference versus
average) with quantile regression lines (2.5th, median and
97.5th percentile lines) is presented. All analyses were done in
SAS 9.3 (SAS Institute, Cary, NC, USA).
RESULTS
The clinical characteristics of the participants are shown for
each validation dataset (Supplementary data, Table S1) and
for the pooled dataset (Table 2).
The performance results of the FAS equation and the recom-
mended eGFR equations are presented, in Supplementary data,
Table S2 for each dataset, and for the pooled data, categorized
according to age group and mGFR below and above 60 mL/
min/1.73 m² (Table 3) and according to age group and gender
(Table 4).
Figure 1 shows the performance of the FAS equation
(Figure 1A) and the combined use of the Schwartz and
CKD-EPI equations (Figure 1B). The median bias over the
full age spectrum is 1.9 mL/min/1.73 m² [interquartile range
(IQR) −6.7–11.0)] for FAS and 5.4 mL/min/1.73 m² (IQR
−2.7–14.5) for the combined use of the Schwartz and CKD-EPI
equations (P < 0.0001).
The external validation (Supplementary data, Table S2)
shows that for children up to 14 years of age, the FAS equation
with Q corresponding with age (Table 1) has smaller constant
and proportional bias in DB1, DB2 andDB3 compared with the
Schwartz equation. Also, the accuracy (P10 and P30) is better
than for the Schwartz equation in these cohorts of children.
The FAS-height equation with Q corresponding with height
(Table 1) performs equivalently for children, but for adoles-
cents and young adults (DB4, DB5), height is a better predictor
than age for Q-values, leading to improved performance of the
FAS-height compared with the FAS equation with Q-age va-
lues. The FAS-height equation shows equivalent performance
Table 1. Q-values [=median serum creatinine in µmol/L (mg/dL)] for the
FAS equation, according to age or height (from refs [4, 5, 10])
Age, years Heighta, cm Qb, μmol/L (mg/dL)
Boys and girls
1 75.0 23 (0.26)
2 87.0 26 (0.29)
3 95.5 27 (0.31)
4 102.5 30 (0.34)
5 110.0 34 (0.38)
6 116.7 36 (0.41)
7 123.5 39 (0.44)
8 129.5 41 (0.46)
9 135.0 43 (0.49)
10 140.0 45 (0.51)
11 146.0 47 (0.53)
12 152.5 50 (0.57)
13 159.0 52 (0.59)
14 165.0 54 (0.61)
Male adolescents
15 172.0 64 (0.72)
16 176.0 69 (0.78)
17 178.0 72 (0.82)
18 179.0 75 (0.85)
19 180.0 78 (0.88)
Male adults
≥20 ≥181.5 80 (0.90)
Female adolescents
15 164.5 57 (0.64)
16 166.0 59 (0.67)
17 166.5 61 (0.69)
18 167.0 61 (0.69)
19 167.5 62 (0.70)
Female adults
≥20 ≥168.0 62 (0.70)
aHeight is the median height of a child or adolescent at the speciﬁed age (Belgian growth
curves).
bMathematical expressions for the Q-age and Q-height relationship for children,
adolescents and young adults can be obtained from Hoste et al. [5].
Table 2. Patient characteristics (N = 6870)
Age group (years) Sex n Mean (SD)
Age, years Height, cm Weigth, kg mGFR, mL/min/1.73 m² SCr, mg/dL SCr, μmol/L
<18 M 414 11.1 (3.1) 141.8 (19.1) 37.0 (14.4) 95.0 (32.8) 0.69 (0.33) 61 (29)
F 321 11.3 (3.3) 140.4 (18.0) 37.2 (14.4) 93.9 (29.2) 0.63 (0.27) 56 (24)
18–70 M 2293 52.6 (12.7) 174.7 (7.1) 81.4 (15.8) 78.4 (28.1) 1.10 (0.50) 97 (44)
F 2078 53.5 (12.7) 162.5 (6.7) 69.8 (16.0) 78.8 (24.3) 0.83 (0.38) 73 (34)
≥70 M 935 77.7 (5.5) 171.4 (7.2) 81.0 (14.4) 53.7 (21.0) 1.35 (0.61) 119 (54)
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as the Schwartz equation in adolescents (DB4) and better re-
sults than the CKD-EPI equation in young adults (DB5). For
adults and older adults, the FAS equation has smaller constant
and proportional bias when compared with the CKD-EPI equa-
tion in 7 of 10 datasets. Precision and accuracy (RMSE, P10 and
P30) was comparable in younger and middle-aged adults and
equivalent or better in older adults.
Categorization according to mGFR (Table 3) shows that the
FAS equation is the best in children <18 years of age, both in the
subgroup <60 and ≥60 mL/min/1.73 m²; the FAS equation is
equivalent to the CKD-EPI equation for adults 18–70 years in
both the <60 and ≥60 mL/min/1.73 m² subgroups and the FAS
equation is better than the CKD-EPI equation for older adults
in the <60 mL/min/1.73 m² subgroup, but performs differently
in the ≥60 mL/min/1.73 m² subgroup.
Categorization according to gender (Table 4) shows that the
FAS equation performs equivalently for male and female chil-
dren and better than the Schwartz equation for females; the FAS
equation performs better than CKD-EPI equation for both
adult males and adult females and also for older males and
females.
Table 5 shows the classiﬁcation comparison of GFR categor-
ies according to mGFR, the FAS equation and the recom-
mended equations (Schwartz and CKD-EPI). This table is
more detailed in the Supplementary data, Tables S3–S5, for
the separate age groups. Using mGFR as the reference method,
the FAS equation correctly classiﬁed subjects into GFR
categories in 68.2% (67.3–69.1) of the cases, compared with
66.6% (65.6–67.5) (P = 0.001) by the combined use of the
two equations (Schwartz, CKD-EPI). In children, FAS correctly
classiﬁed subjects into GFR categories in 74.8% (72.1–77.5) of
cases, compared with 77.8% (75.2–80.3) (P = 0.037) for the
Schwartz equation. In adults, FAS correctly classiﬁed subjects
into GFR categories in 65.7% (64.5–66.9) of cases, compared
with 63.6% (62.4–64.8) (P = 0.0003) for the CKD-EPI equation.
Finally, in the older adults subgroup, FAS correctly classiﬁed
subjects into GFR categories in 71.5% (69.7–73.3) of cases,
compared with 69.4% (67.5–71.2) (P = 0.038) for the CKD-EPI
equation. However, in this last age group, if the CKD-EPI equa-
tion predicts an eGFR ≥60 mL/min/1.73 m², it is correct in
74.9% of cases (compared with 84.7% for FAS) and if the
CKD-EPI predicts an eGFR <60 mL/min/1.73 m², it is correct
in 92.7% of cases (compared with 83.1% for FAS).
DISCUSSION
In this study, we derived a novel eGFR equation based on the
concept of population-normalized SCr, denoted as SCr/Q. By
extending the previously published [4] and validated paediatric
equation [5, 28–30] and by connecting this equation to the pre-
viously published [8] and validated BIS1 equation [18, 31–33],
we developed a new equation, called the FAS equation, introdu-
cing continuity across the full age-spectrum andwith important
Table 3. Prediction performance results of different eGFR equations on the pooled databases according to age group and measured GFR categories (mGFR
below or above 60 mL/min/1.73 m2)










Children and adolescents <18 years
All (n = 735)
mGFR = 94.5
FAS 20.1 (18.5, 21.6) −1.7 (−3.1, −0.2)*,† 1.01 (0.99, 1.03)*,† 40.1 (36.6, 43.7) 87.5 (85.1, 89.9)*
FAS-height 19.8 (18.1, 21.4) −2.7 (−4.1, −1.3)*,‡ 1.00 (0.98, 1.01)*,‡ 41.9 (38.3, 45.5) 88.8 (86.6, 91.1)†
Schwartz 21.7 (19.5, 23.7) 6.0 (4.5, 7.5)†,‡ 1.09 (1.07, 1.11)†,‡ 40.1 (36.6, 43.7) 83.8 (81.1, 86.5)*,†
mGFR < 60 (n = 99)
mGFR = 45.1
FAS 14.6 (8.5, 18.9) 6.2 (3.6, 8.9)*,† 1.15 (1.09, 1.21)*,† 34.3 (24.8, 43.9) 75.8 (67.2, 84.3)
FAS-height 13.5 (4.2, 18.6) 4.7 (2.2, 7.2)*,‡ 1.12 (1.06, 1.17)*,‡ 39.4 (25.6, 49.2) 77.8 (69.4, 86.1)*
Schwartz 16.7 (8.2, 22.1) 9.4 (6.7, 12.2)†,‡ 1.22 (1.16, 1.28)†,‡ 31.3 (22.0, 40.6) 70.7 (61.6, 79.8)*
mGFR ≥ 60 (n = 636)
mGFR = 102.2
FAS 20.8 (19.1, 22.4) −2.9 (−4.5, −1.3)*,† 0.99 (0.97, 1.00)*,† 41.0 (37.2, 44.9) 89.3 (86.9, 91.7)*
FAS-height 20.6 (18.9, 22.3) −3.8 (−5.4, −2.3)*,‡ 0.98 (0.96, 0.99)*,‡ 42.3 (38.4, 46.1) 90.6 (88.3, 92.8)†
Schwartz 22.4 (20.0, 24.5) 5.4 (3.7, 7.1)†,‡ 1.07 (1.05, 1.09)†,‡ 41.5 (37.7, 45.3) 85.8 (83.1, 88.6)*,†
Adults 18–70 years
All (n = 4371)
mGFR = 78.6
FAS 17.2 (16.6, 17.8) 5.0 (4.5, 5.5)* 1.12 (1.11, 1.12)* 40.4 (38.9, 41.9)* 81.6 (80.4, 82.7)
CKD-EPI 16.4 (15.8, 16.9) 6.3 (5.9, 6.8)* 1.13 (1.12, 1.14)* 42.5 (41.1, 44.0)* 81.9 (80.7, 83.0)
mGFR < 60 (n = 1089) FAS 19.0 (17.7, 20.2) 13.4 (12.6, 14.2)* 1.35 (1.33, 1.37)* 19.1 (16.8, 21.4)* 52.2 (49.3, 55.2)*
mGFR = 42.3 CKD-EPI 19.2 (18.1, 20.3) 12.7 (11.8, 13.5)* 1.31 (1.29, 1.34)* 21.9 (19.4, 24.3)* 55.2 (52.2, 58.1)*
mGFR ≥ 60 (n = 3282) FAS 16.6 (15.9, 17.2)* 2.2 (1.6, 2.7)* 1.04 (1.03, 1.04)* 47.5 (45.8, 49.2)* 91.3 (90.3, 92.3)
mGFR = 90.6 CKD-EPI 15.3 (14.7, 15.8)* 4.2 (3.7, 4.7)* 1.07 (1.06, 1.07)* 49.4 (47.7, 51.1)* 90.7 (89.7, 91.7)
Older adults ≥70 years
All (n = 1764)
mGFR = 55.6
FAS 11.2 (10.7, 11.7)* −1.1 (−1.6, −0.6)* 1.02 (1.01, 1.03)* 39.7 (37.5, 42.0)* 86.1 (84.4, 87.7)*
CKD-EPI 12.9 (12.4, 13.4)* 5.6 (5.1, 6.2)* 1.13 (1.12, 1.15)* 35.0 (32.8, 37.3)* 77.6 (75.7, 79.6)*
BIS1
a
12.0 (11.4, 12.6) −1.2 (−1.9, −0.6) 1.05 (1.03, 1.07) 34.7 (32.0, 37.4) 81.8 (79.7, 84.0)
mGFR < 60 (n = 986)
mGFR = 40.7
FAS 9.5 (8.8, 10.1)* 2.2 (1.6, 2.7)* 1.09 (1.07, 1.11)* 36.6 (33.6, 39.6)* 81.0 (78.6, 83.5)*
CKD-EPI 13.1 (12.3, 13.8)* 6.9 (6.2, 7.6)* 1.19 (1.17, 1.21)* 29.5 (26.7, 32.4)* 67.7 (64.8, 70.7)*
BIS1a 9.7 (9.0, 10.3) 3.7 (3.0, 4.4) 1.16 (1.13, 1.18) 35.3 (31.8, 38.8) 75.4 (72.2, 78.5)
mGFR ≥ 60 (n = 778)
mGFR = 74.4
FAS 13.1 (12.3, 13.8) −5.2 (−6.1, −4.4)* 0.94 (0.93, 0.95)* 43.7 (40.2, 47.2) 92.4 (90.6, 94.3)
CKD-EPI 12.7 (12.1, 13.3) 4.1 (3.2, 4.9)* 1.07 (1.06, 1.08)* 42.0 (38.6, 45.5) 90.1 (88.0, 92.2)
BIS1a 14.8 (13.7, 15.7) −8.6 (−9.7, −7.5) 0.90 (0.88, 0.91) 33.9 (29.6, 38.1) 91.5 (89.0, 94.0)
The same symbols (*,†,‡) within each subgroup and column indicate signiﬁcant differences (paired t-test for constant and proportional bias, McNemar's test for P10 and P30 =% of subjects
with an eGFR value within 10% and 30% of measured GFR).
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advantages over the currently recommended equations. First, it
is a reasonable alternative to commonly used existing eGFR
equations for children, adolescents, young adults, adults and
older adults, as the FAS equation is valid across the full age-
spectrum. Second, the correction for age (for children) and
sex is at the level of SCr, not at the level of GFR, which makes
sense, as there is a clear increase in SCr with age during child-
hood and a difference between sexes, but the average GFR, ex-
pressed in mL/min/1.73 m², is not age dependent in children
and the (clinically relevant) difference in GFR between sexes
is still a matter of debate [34, 35]. The FAS equation, therefore,
does not require further correction for age or sex, and probably
not for other ethnicities, although Q-values speciﬁc for other
ethnicities still need to be obtained [12]. Third, the equation
solves the discontinuity when switching from paediatric to
adult eGFR and the discontinuity between adult and the BIS1
equation developed for older adults. Key in requiring continuity
between paediatric and adult equation is the introduction of an
age cut-off, where renal decline begins. Up to now, the recom-
mended adult equations (MDRD, CKD-EPI) have assumed
that the decline starts at the age of 18 years, which is an unrea-
sonable assumption. Indeed, some authors have shown that the
decrease in GFR is continuous from the age of 40 or 50 years on
[36–41] and others point out that it starts continuously but
accelerates (and doubles) from the fourth or ﬁfth decade on
[34, 35, 42, 43]. A rule of thumb is that the GFR stays within
the normal range until the age of 40 years and then declines
at approximately 1 mL/min/year [44]. This decline appears in
both males and females. This decrease in GFR might vary ac-
cording to the studies ranging from 6 [45] to 12 mL/min/1.73
m² per decade [39]. During the development of our new equa-
tion, we assumed that the paediatric equation could be used up
to an age cut-off and by mathematically matching our equation
with the BIS1 equation we found that this age cut-off is 40 years,
conﬁrming most of the literature, with a decline rate constant
equal to 0.988Age. Fourth, the equation is simple and intuitive
and every coefﬁcient in the equation has a speciﬁc meaning: (i)
107.3 mL/min/1.73 m² may be considered as the average GFR
value for healthy children, adolescents and young adults. This
value was obtained from a previously published meta-analysis
[4] and is supported by the literature studies [34]. (ii) The equa-
tion assumes an inverse relationship with SCr, or more specif-
ically with SCr/Q, where the exponent is simply −1, and not
−1.209 (CKD-EPI), or −1.154 (MDRD) or −0.87 (BIS1).
This inverse relationship simpliﬁes the overall relationship.
(iii) SCr/Q = 1 corresponds to the average healthy subject and
is independent of age and sex because all age/sex information is
absorbed in the Q-value. (iv) The age decline rate matches the
decline rate of the BIS1 equation, i.e. 0.988Age, which is equiva-
lent to about 1 mL/min/1.73 m²/year.
The large external validation shows that the FAS equation is
the most unbiased equation in this comparison and demon-
strates better performance than the Schwartz and CKD-EPI
equations. All equations performed worse in the pooled data-
base subsets deﬁned by mGFR <60 mL/min/1.73 m², but FAS
shows better accuracy and precision, although for older adults
with mGFR ≥60 mL/min/1.73 m², FAS underestimates and
CKD-EPI overestimates mGFR, an observation also made by
Fan et al. [46]. As the FAS equation has been designed based
on SCr/Q requirements valid for the healthy population, it
was expected that the FAS equation would perform better in
the healthy and general population than in the CKD popula-
tion, which is conﬁrmed in this validation study; however, the
validation results in the mGFR <60mL/min/1.73 m² subgroups
Table 4. Prediction performance results of different eGFR equations on the pooled databases according to age group and gender










Children and adolescents <18 years
Males
(n = 414) (mGFR = 95.0)
FAS 20.0 (18.1, 21.7) −5.2 (−7.0, −3.3)* 0.97 (0.95, 0.99)* 39.6 (34.9, 44.3) 87.4 (84.2, 90.6)
FAS-height 19.4 (17.5, 21.1) −5.5 (−7.3, −3.7)† 0.96 (0.95, 0.98)† 41.3 (36.5, 46.1) 89.4 (86.4, 92.4)
Schwartz 19.8 (17.5, 22.0) +2.9 (1.0, 4.8)*,† 1.05 (1.03, 1.07)*,† 43.7 (38.9, 48.5) 88.2 (85.0, 91.3)
Females
(n = 321) (mGFR = 93.9)
FAS 20.2 (17.2, 22.8) 2.8 (0.6, 5.0)*,† 1.06 (1.04, 1.09)*,† 40.8 (35.4, 46.2) 87.5 (83.9, 91.2)*
FAS-height 20.4 (17.2, 23.1) 1.0 (1.3, 3.2)*,‡ 1.04 (1.01, 1.06)*,‡ 42.7 (37.2, 48.1)* 88.2 (84.6, 91.7)†
Schwartz 23.9 (19.9, 27.3) 10.0 (7.6, 12.4)†,‡ 1.14 (1.11, 1.16)†,‡ 35.5 (30.3, 40.8)* 78.2 (73.7, 82.7)*,†
Adults 18–70 years
Males
(n = 2293) (mGFR = 78.4)
FAS 17.8 (17.0, 18.6) 4.9 (4.2, 5.6)* 1.12 (1.11, 1.13) 38.8 (36.8, 40.8)* 79.2 (77.6, 80.9)*
CKD-EPI 16.3 (15.5, 17.0) 5.2 (4.6, 5.9)* 1.12 (1.11, 1.13) 42.0 (40.0, 44.0)* 81.4 (79.8, 83.0)*
Females
(n = 2078) (mGFR = 78.8)
FAS 16.6 (15.6, 17.4) 5.0 (4.3, 5.7)* 1.11 (1.10, 1.12)* 42.2 (40.1, 44.3) 84.1 (82.5, 85.7)*
CKD-EPI 16.5 (15.7, 17.2) 7.5 (6.9, 8.1)* 1.14 (1.12, 1.15)* 43.1 (41.0, 45.2) 82.4 (80.7, 84.0)*
Older adults ≥70 years
Males
(n = 935) (mGFR = 53.7)
FAS 11.0 (10.3, 11.8)* −0.6 (−1.3, 0.1)* 1.04 (1.02, 1.06)* 39.8 (36.6, 42.9)* 84.9 (82.6, 87.2)*
CKD-EPI 12.6 (11.9, 13.3)* 5.3 (4.5, 6.0)* 1.14 (1.12, 1.16)* 35.0 (31.9, 38.0)* 76.8 (74.1, 79.5)*
BIS1a 12.1 (11.1, 12.9) −1.1 (−2.1, −0.2) 1.07 (1.04, 1.10) 34.5 (30.7, 38.3) 79.3 (76.1, 82.5)
Females
(n = 829) (mGFR = 57.7)
FAS 11.4 (10.6, 12.1) −1.6 (−2.4, −0.8)* 1.00 (0.99, 1.02)* 39.7 (36.3, 43.0)* 87.3 (85.1, 89.6)*
CKD-EPI 13.2 (12.5, 13.9) 6.0 (5.2, 6.8)* 1.13 (1.11, 1.15)* 35.1 (31.8, 38.4)* 78.5 (75.7, 81.3)*
BIS1a 11.9 (11.1, 12.7) −1.3 (−2.3, −0.4) 1.03 (1.01, 1.05) 35.0 (31.4, 38.9) 84.5 (81.5, 87.4)
The same symbols (*,†,‡) within each subgroup and column denote signiﬁcant differences (paired t-test for constant and proportional bias, McNemar's test for P10 and P30 = % of subjects
with an eGFR value within 10% and 30% of measured GFR).
95% CI, 95% conﬁdence interval; FAS, full age spectrum equation; eGFR eq., estimated glomerular ﬁltration rate equation; mGFR, measured glomerular ﬁltration rate; CKD-EPI, Chronic
Kidney Disease Epidemiology Collaboration equation; BIS1, Berlin Initiative Study; RMSE, root mean square error.
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are not worse than with the CKD-EPI equation. The FAS equa-
tion performed equivalent to the Schwartz equation for male
children but much better for female children. The FAS equa-
tion, with Q based on age, performed reasonably well for
adolescents, but worse than the Schwartz equation. However,
it has been shown previously that the same (FAS-height) equa-
tion using a height-dependent Q-value (FAS-height) per-
formed better than the Schwartz equation [5, 28, 29]. The fact
F IGURE 1 : (A) Difference between estimated (FAS equation) and measured GFR versus the average of both methods. Quantile regression lines
(2.5th, 50th and 97.5th percentiles) are shown, without excluding any data. Median difference = 1.9 mL/min/1.73 m². (B) Difference between
estimated (Schwartz up to age 18 years, CKD-EPI beyond 18 years) and measured GFR versus the average of both methods. Quantile regression
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that the Schwartz equation shows a better categorization into
GFR categories than FAS is due to the large number of children
with mGFR >90 mL/min/1.73 m² in our study, combined with
the systematic overestimation of mGFR by the Schwartz equa-
tion. An advantage of the age-dependent FAS equation over the
height-dependent FAS equation for children and adolescents is
that it can be used by the clinical laboratory, where height infor-
mation is usually not available. Therefore, automatic reporting
of FAS predictions along with the SCr value by the clinical la-
boratory can be done for all ages, without continuity problems
at the paediatric–adult and adult–elderly transition. The FAS
equation was equivalent to the CKD-EPI equation for adult
males, slightly better for adult females and superior in the oldest
adults, and was also better than the BIS1 equation for older
adults, and again slightly better for females than for males
(Table 4). Overall, these approximately equivalent performance
results for males and females indicate that correction at the SCR
level for gender works well and is equivalent to corrections
made at the GFR level. Finally, the overall classiﬁcation into
mGFR categories based on FAS and the established equations
is approximately equivalent (Table 5).
This study has some limitations. First, the FAS equation does
not improve the imprecision, which remains a problem for all
currently used and recommended eGFR equations. Second, as
Belgium is central in Europe, the Belgian growth curves are
quite representative for European children, however, matching
national growth curves to Q-values might be more optimal
[28, 29]. For adults, the constant Q-values are very robust.
Third, validation data in the age range of 20–40 years includes
a limited number of healthy subjects. Fourth, cystatin C equa-
tions are not considered in the comparison. Fifth, in case of
severe muscle wasting (very low SCr), the power coefﬁcient of
−1 may cause an overestimation of GFR, but this is a limitation
of all SCr-based equations [47, 48]. Finally, the validation is for
Caucasians only. We believe that the FAS equation can be ex-
tended to other ethnicities as well, with appropriateQ-values to
normalize SCr, but this will require further studies.
In conclusion, the FAS equation is an alternative to the
Schwartz, CKD-EPI and BIS1 equations. It enables continuity
of eGFR prediction across the full age-spectrum and has a very
simple form, especially for adults, and older adults where ﬁxed
Q-values can be used. The FAS equation is of particular interest
for longitudinal follow-up, but this potentially added value
needs to be conﬁrmed in further studies.
SUPPLEMENTARY DATA
Supplementary data are available online at http://ndt.oxford
journals.org.
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